title: Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
authors.forename: Pieter
authors.initials: P
authors.lastname: Evenepoel
authors.forename: Bjorn
authors.initials: B
authors.lastname: Meijers
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D001808:Blood Vessels / Q000473:pathology; D002114:Calcinosis; D017610:Calcium Compounds / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D054559:Hyperphosphatemia / Q000209:etiology / Q000517:prevention & control; D007811:Lanthanum / Q000627:therapeutic use*; D028044:Phosphate-Binding Proteins / Q000378:metabolism / Q000627:therapeutic use*; D010710:Phosphates / Q000378:metabolism; D011073:Polyamines / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000069603:Sevelamer
chemical_list: D000085:Acetates; D017610:Calcium Compounds; D002614:Chelating Agents; D028044:Phosphate-Binding Proteins; D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; C120662:calcium acetate